Merck’s $780 Million Acquisition of Exelead

McDermott Will & Emery represented Merck KGaA in the transaction. Legance – Avvocati Associati advised the shareholders of Exelead Inc.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, entered into a definitive agreement to acquire Exelead, a biopharmaceutical contract development and manufacturing organization (CDMO) that specializes in complex injectable formulations, for US $780 million.

This transaction will enhance Merck KGaA, Darmstadt, Germany’s more than 20 years of experience producing lipids, one of the critical components for the formulation of mRNA therapeutics including COVID-19 vaccines as well as its mRNA manufacturing capabilities.

The transaction was announced on January 6, 2022 and is expected to close in Q1 2022 subject to regulatory clearances and other customary closing conditions.

The McDermott team was led by Byron Kalogerou (Picture), Jennifer Bock and Sheldon Hughes and included Rebecca Dufur, Michael Willey, Michael Siekman, Jed Gordon, Hala Mourad, Anisa Mohanty, Brian Malkin, Daniel Doron, Abigail Kagan, Jeffery Holdvogt, Ray Jacobsen, Hendrik Viaene, Ty Carson, Karolien Van Der Putten, David Wolff, Garrett Kurtzweil, David Levine, Fran Forte, Todd McClelland, David Gacioch, Ettore Scandale, Massimiliano Moruzzi, Michael Bruno and Keith Hagan.

The Merck KGaA, Darmstadt, Germany in-house legal team counsel was led by Rose Brounts, Head of Legal M&A, Post-Merger Integration and Finance and Alexander Krueger, Corporate Counsel, Legal – M&A, Post-Merger Integration and Finance.

Legance – Avvocati Associati advised the shareholders of Exelead Inc. with a team led by Alberto Giampieri, Andrea Botti, Achille Caliò Marincola, Stefano Bandini and Cristina Marani for M&A matters. Lorenzo Silveri Gentiloni and Ada Esposito acted on regulatory matters of Life Sciences and Healthcare.

Involved fees earner: Stefano Bandini – Legance; Andrea Botti – Legance; Achille Caliò Marincola – Legance; Ada Esposito – Legance; Lorenzo Gentiloni Silveri – Legance; Alberto Giampieri – Legance; Cristina Marani – Legance; Jennifer Bock – McDermott Will & Emery; Michael Bruno – McDermott Will & Emery; Timothy Carson – McDermott Will & Emery; Daniel Doron – McDermott Will & Emery; Rebecca Dufur – McDermott Will & Emery; Fran Forte – McDermott Will & Emery; David Gacioch – McDermott Will & Emery; Edward Gordon – McDermott Will & Emery; Keith Hagan – McDermott Will & Emery; Jeffrey Holdvogt – McDermott Will & Emery; Sheldon Hughes – McDermott Will & Emery; Ray Jacobsen – McDermott Will & Emery; Abigail Kagan – McDermott Will & Emery; Byron Kalogerou – McDermott Will & Emery; Garrett Kurtzweil – McDermott Will & Emery; David Levine – McDermott Will & Emery; Brian Malkin – McDermott Will & Emery; Todd McClelland – McDermott Will & Emery; Anisa Mohanty – McDermott Will & Emery; Massimiliano Moruzzi – McDermott Will & Emery; Hala Mourad – McDermott Will & Emery; Ettore Scandale – McDermott Will & Emery; Michael Siekman – McDermott Will & Emery; Karolien Van der Putten – McDermott Will & Emery; Hendrik Viaene – McDermott Will & Emery; Michael Willey – McDermott Will & Emery; David Wolff – McDermott Will & Emery;

Law Firms: Legance; McDermott Will & Emery;

Clients: Exelead Inc.; Merck KGaA;